MARKET

RARX

RARX

Ra Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.24
-0.51
-1.09%
After Hours: 46.24 0 0.00% 16:00 10/18 EDT
OPEN
46.70
PREV CLOSE
46.75
HIGH
46.74
LOW
46.04
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
47.08
52 WEEK LOW
11.27
MARKET CAP
2.17B
P/E (TTM)
-23.6800
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RARX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RARX News

  • ACT NOW: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout
  • ACCESSWIRE.1d ago
  • 3 Companies to Watch At Kidney Week 2019
  • MotleyFool.com.2d ago
  • SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - RARX, DOVA, ACHN
  • ACCESSWIRE.2d ago
  • READ NOW: Monteverde & Associates PC Continues Investigations on the Following Merger
  • ACCESSWIRE.3d ago

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About RARX

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.
More

Webull offers Ra Pharmaceuticals Inc (RARX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.